Clinical trial · Observational
Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
NCT03355235CI-TRIAL-00046861completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assessment, Self-Administered Gerocognitive Exam (SAGE) or the healthcare applied Montreal Cognitive Assessment (MoCA) assessment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stem Cell Transplant Complications | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cognitive assessment using standardized tools
- description
- cognitive assessment using standardized tools pre and post transplant.
Primary outcomes (6)
- measure
- Scores of the PROMIS Cognitive Function, short form 8a
- timeFrame
- Before to approximately 100 days after transplant
- description
- Will be assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Cognitive Function, short form 8a. The mean scores (and standard deviations) for each time points will be presented.
- measure
- Scores of the Self-Administered Gerocognitive Exam (SAGE)
- timeFrame
- Before to approximately 100 days after transplant
- description
- Will be assessed by the Self-Administered Gerocognitive Exam (SAGE). The mean scores (and standard deviations) for each time points will be presented.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with multiple myeloma * Patients who will undergo pre-transplant evaluation with intentions to proceed to autologous stem cell transplant after stem cell collection. * Patients willing and able to understand and sign an informed consent form * Patients 18 yrs of age or older Exclusion Criteria: * Patients with unstable psychiatric illness within the past 3 months of study enrollment. * Patients who are considered unable to perform study evaluations at the investigator's discretion. * Patients who are unable to read. (If patients require reading glasses, they must be worn at time of test.) * Patients who do not proceed to stem cell transplant within 60 days of stem cell collection will be excluded from study. * Patients who receive more than one cycle of chemotherapy between the time of stem cell collection and transplant will be excluded from study.
References
Publications (0)
Data not yet available
No reference posted for this study.